Coreceptors--Implications for HIV Pathogenesis and Therapy

Last year, the second of the two receptors that HIV uses to enter and infect human cells was identified. In his Perspective, Moore discusses the resulting revolution in thought about how these coreceptor molecules can influence the progress of AIDS and what their existence means for future therapies.

[1]  D. Ho,et al.  High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[2]  D. Goeddel,et al.  Selective attraction of monocytes and T lymphocytes of the memory phenotype by cytokine RANTES , 1990, Nature.

[3]  J. Moore,et al.  Virions of primary human immunodeficiency virus type 1 isolates resistant to soluble CD4 (sCD4) neutralization differ in sCD4 binding and glycoprotein gp120 retention from sCD4-sensitive isolates , 1992, Journal of virology.

[4]  H. Schuitemaker,et al.  Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population , 1992, Journal of virology.

[5]  D. Richman,et al.  The impact of the syncytium-inducing phenotype of human immunodeficiency virus on disease progression. , 1994, The Journal of infectious diseases.

[6]  A. Trkola,et al.  Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG , 1995, Journal of virology.

[7]  J. Sodroski,et al.  Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding , 1995, Journal of virology.

[8]  J J Goedert,et al.  Genetic Restriction of HIV-1 Infection and Progression to AIDS by a Deletion Allele of the CKR5 Structural Gene , 1996, Science.

[9]  Steven M. Wolinsky,et al.  The role of a mutant CCR5 allele in HIV–1 transmission and disease progression , 1996, Nature Medicine.

[10]  D. Ho,et al.  HIV-1 subtype and second-receptor use , 1996, Nature.

[11]  M. Baggiolini,et al.  HIV blocked by chemokine antagonist , 1996, Nature.

[12]  Richard A Koup,et al.  Homozygous Defect in HIV-1 Coreceptor Accounts for Resistance of Some Multiply-Exposed Individuals to HIV-1 Infection , 1996, Cell.

[13]  J. Mascola,et al.  Human immunodeficiency virus type 1 neutralizing antibody serotyping using serum pools and an infectivity reduction assay. , 1996, AIDS research and human retroviruses.

[14]  V. Harden,et al.  Chemokines and HIV–1 second receptors , 1996, Nature Medicine.

[15]  Anthony S. Fauci,et al.  Host factors and the pathogenesis of HIV-induced disease , 1996, Nature.

[16]  P. Kaleebu,et al.  Neutralization serotypes of human immunodeficiency virus type 1 field isolates are not predicted by genetic subtype. The WHO Network for HIV Isolation and Characterization , 1996, Journal of virology.

[17]  Marc Parmentier,et al.  Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene , 1996, Nature.

[18]  Steven M. Wolinsky,et al.  Relative resistance to HIV–1 infection of CD4 lymphocytes from persons who remain uninfected despite multiple high–risk sexual exposures , 1996, Nature Medicine.

[19]  J. Albert,et al.  Sensitivity to inhibition by beta-chemokines correlates with biological phenotypes of primary HIV-1 isolates. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[20]  William C. Olson,et al.  CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5 , 1996, Nature.

[21]  C. Mackay,et al.  The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[22]  P. Piot,et al.  The neutralization relationship of HIV type 1, HIV type 2, and SIVcpz is reflected in the genetic diversity that distinguishes them. , 1997, AIDS research and human retroviruses.

[23]  R. Connor,et al.  Change in Coreceptor Use Correlates with Disease Progression in HIV-1–Infected Individuals , 1997, The Journal of experimental medicine.

[24]  J. Sodroski,et al.  Utilization of C-C chemokine receptor 5 by the envelope glycoproteins of a pathogenic simian immunodeficiency virus, SIVmac239 , 1997, Journal of virology.

[25]  D. Montefiori,et al.  Antibody-mediated neutralization of primary isolates of human immunodeficiency virus type 1 in peripheral blood mononuclear cells is not affected by the initial activation state of the cells , 1997, Journal of virology.